Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab switch study in previously treated wet age-related macular degeneration
ACTRN12621000624886Phase 4Withdrawn
- Sponsor
- Clinical Professor Nitin Verma
- Start
- May 2021
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of brolucizumab in exudative macular degeneration, sponsored by Clinical Professor Nitin Verma. Primary endpoints: Proportion of participants with persistent retinal fluid and Mean change in central retinal thickness. Planned start May 2021; status: withdrawn.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ACTRN12621000624886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000624886.